TD Asset Management
DSGN icon

TD Asset Management’s Design Therapeutics DSGN Stock Holding History

TD Asset Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,318
Closed -$274K – 1460
2022
Q3 		$274K Sell
16,318
-7,300
-31% -$145K ﹤0.01% 1377
2022
Q2 		$331K Sell
23,618
-20,700
-47% -$280K ﹤0.01% 1346
2022
Q1 		$716K Sell
44,318
-21,400
-33% -$328K ﹤0.01% 1295
2021
Q4 		$1.41M Hold
65,718
– – ﹤0.01% 1214
2021
Q3 		$965K Buy
65,718
+44,396
+208% +$738K ﹤0.01% 1262
2021
Q2 		$330K Hold
21,322
– – ﹤0.01% 1434
2021
Q1 		$638K Buy
+21,322
New +$719K ﹤0.01% 1356

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TD Asset Management's DSGN Position: Q4 2022 in Review

TD Asset Management sold out of Design Therapeutics (DSGN) in Q4 2022, closing a stake of 16,318 shares — an estimated $274K sold.

TD Asset Management first reported a position in DSGN in Q1 2021 and held it in 7 quarters. The position peaked at $1.41M in Q4 2021. 83 funds tracked by Wall St. Rank hold DSGN as of Q4 2022.

  • TD Asset Management reported no remaining Design Therapeutics position as of Q4 2022 after selling out during the quarter.
  • TD Asset Management sold 16,318 Design Therapeutics shares in Q4 2022, an estimated $274K.
  • TD Asset Management first reported a position in Design Therapeutics in Q1 2021 and held it in 7 quarters.
  • TD Asset Management's Design Therapeutics position peaked at $1.41M in Q4 2021.
  • 83 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2022.

Based on TD Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.